The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group, which concluded that there is insufficient evidence of benefit to recommend deployment.
While the Medicines and Healthcare products Regulatory Agency gave a Conditional Marketing Authorisation to Evusheld in March 2022, it did so noting that there a lack of data on its response to the Omicron variant. AstraZeneca has made Evusheld available privately in the UK, which is a matter for individual patients and their healthcare providers. It is distinct from any Government consideration of its use within the National Health Service.